Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: A pooled analysis

The Lancet Respiratory Medicine

Volumn 4, Issue 5, 2016, Pages 381-389

  Kreuter, Michael ^a,b   Wuyts, Wim ^c   Renzoni, Elisabetta ^d,e   Koschel, Dirk ^f   Maher, Toby M ^d,e   Kolb, Martin ^g   Weycker, Derek ^h   Spagnolo, Paolo ⁱ   Kirchgaessler, Klaus Uwe ^j   Herth, Felix J F ^a,b   Costabel, Ulrich ^k  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b German Center for Lung Research   (Germany)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f Fachkrankenhaus Coswig   (Germany)

^g MCMASTER UNIVERSITY   (Canada)

^h POLICY ANALYSIS INC PAI   (United States)

ⁱ UNIVERSITY OF BASEL   (Switzerland)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

^k RUHRLANDKLINIK   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PIRFENIDONE; PLACEBO; PROTON PUMP INHIBITOR; ANTACID AGENT; PYRIDONE DERIVATIVE;

ADULT; AGED; ANTACID THERAPY; ARTICLE; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG EFFECT; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; HOSPITAL ADMISSION; HUMAN; INFECTION; INFECTION RISK; LUNG FUNCTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; SURVIVAL; THERAPY; COMPLICATION; DISEASE EXACERBATION; DRUG EFFECTS; KAPLAN MEIER METHOD; LUNG; META ANALYSIS; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VITAL CAPACITY; WALK TEST;

AGED; ANTACIDS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; EXERCISE TOLERANCE; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; KAPLAN-MEIER ESTIMATE; LUNG; MALE; MIDDLE AGED; PATIENT ADMISSION; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VITAL CAPACITY; WALK TEST;

EID: 84961876871     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)00067-9     Document Type: Article

References (26)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
2. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769.
3. King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2083-2092.
4. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2071-2082.
5. Katz PO, Gerson LB, Vela MF Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013, 108:308-328.
6. Hyldgaard C, Hilberg O, Muller A, Bendstrup E A cohort study of interstitial lung diseases in central Denmark. Respir Med 2014, 108:793-799.
7. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006, 27:136-142.
8. Tobin RW, Pope CE, Pellegrini CA, Emond MJ, Sillery J, Raghu G Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 158:1804-1808.
9. Behr J, Kreuter M, Hoeper MM, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J 2015, 46:186-196.
10. Sonnenberg A Effects of environment and lifestyle on gastroesophageal reflux disease. Dig Dis 2011, 29:229-234.
11. Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184:1390-1394.
12. Lee JS, Song JW, Wolters PJ, et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2012, 39:352-358.
13. Raghu G, Meyer KC Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy?. Eur Respir J 2012, 39:242-245.
14. Hu X, Lee JS, Pianosi PT, Ryu JH Aspiration-related pulmonary syndromes. Chest 2015, 147:815-823.
15. Savarino E, Carbone R, Marabotto E, et al. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J 2013, 42:1322-1331.
16. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015, 192:e3-19.
17. Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013, 1:369-376.
18. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 1998, 113:619-624.
19. Pencina MJ, D'Agostino RBS, D'Agostino RB, Vasan RS Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172.
20. Allison PD Survival analysis using SAS: a practical guide 2010, SAS Institute, Cary, NC, USA. 2nd edn.
21. Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006, 129:794-800.
22. Linden PA, Gilbert RJ, Yeap BY, et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg 2006, 131:438-446.
23. Ibrahim EH, Tracy L, Hill C, Fraser VJ, Kollef MH The occurrence of ventilator-associated pneumonia in a community hospital: risk factors and clinical outcomes. Chest 2001, 120:555-561.
24. Myles PR, Hubbard RB, Gibson JE, Pogson Z, Smith CJ, McKeever TM The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort. Pharmacoepidemiol Drug Saf 2009, 18:697-703.
25. Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax 2013, 68:155-162.
26. Noth I, Zangan SM, Soares RV, et al. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J 2012, 39:344-351.